Breathing

Wellness Centers®

®

The Science of

Epigenetics in Dentistry

The Human Genome Project was an international scientific research project with the goal of determining the sequence of base pairs that make up human DNA. The project was declared complete of April 14, 2003. Four years after the completion of the project in 2007, the journal Science announced that epigenetics was the ‘breakthrough of the year’. In 2009, Time magazine considered it second of the top ten discoveries in 2009.

 

The remarkable research and fascinating findings achieved in the early days of the Human Genome Project have impacted life science in immeasurable ways in the decades since its completion.  However, with the advent of the Human Epigenome Project new horizons have emerged.

 

At Vivos Therapeutics, our research teams embark on a relentless pursuit to explore the implications and possible applications of craniofacial epigenetics.

 

 

 

Craniofacial

Epigenetics

Craniofacial epigenetics is an emerging field with the potential of addressing certain ‘modern’ craniofacial diseases and health conditions impacting our world.

 

At Vivos, we are making significant contributions in this important field.

 

We make our contributions in four key areas:

 

  1. Research Through Clinical Trials
  2. Product Design & Development
  3. Practical Applications Through Innovative Clinical Protocols.
  4. Professional Education & Public Awareness

The Science of

Pneumopedics®

Pneumopedics® is an emerging field based on physiologic remodeling of the upper airway via treatment-induced changes.

 

The Vivos System® incorporates both Craniofacial epigenetics and Pneumopedics® in its biomimetic oral appliance therapy protocols for addressing midfacial hypoplasia and mandibular retrognathia associated with deficient upper airway, breathing and sleep issues.

 

Pneumpoedics® represents a significant therapeutic protocol of the principle findings of craniofacial epigenetics.

 

 

Applied

Medical Science

Vivos provides advanced education to professionals and clinicians across the healthcare spectrum to enable them to appreciate Pneumopedics® and craniofacial epigenetics in their healthcare practice.

 

Our programs are also designed to help practitioners obtain the clinical skills needed to apply craniofacial epigenetics and Pneumopedics® in their treatment planning and protocols.

 

Our core aim here is to provide understanding and the practical applications to put our findings over the last 10 years or so to work in real life.

 

 

Contributions To

Breathing Wellness

Millions of people of all ages suffer from conditions described in the medical literature as maxillary hypoplasia and/or mandibular retrognathia/retrusion.

 

This all too common a condition, where the upper and lower jaws do not fully develop and often results in a compromised upper airway.

 

Individuals who suffer from these conditions may develop sleep disordered breathing, including obstructive sleep apnea or, causing them to periodically stop breathing during sleep.

 

Vivos is investing in ongoing clinical research and clinical trials to expand its existing portfolio of therapeutic-grade biomimetic oral appliances for the treatment of midfacial hypoplasia and/or mandibular retrognathia/retrusion.

  • Crooked Teeth
  • Mouth Breathing
  • Nasal Obstruction
  • Improper Tongue placement
  • Narrow Dental Arches
  • Vivos mRNA® Appliance
  • Vivos DNA® Appliance*
  • Vivos Guides

Class II

Class I

Class I

*Class II Application Pending

  • Reduced or Elimination of Mouth Breathing/Snoring
  • Reduced or Elimination of Nasal Obstruction
  • Proper Tongue Positioning
  • Enhance Upper Airway Volume and Reduced Nighttime Airway Collapse
  • Straighter Teeth
  • Reduced or eliminated TMJ pain/headaches
  • Enhanced facial symmetry

 

 

Midfacial hypoplasia and mandibular retrognathia are conditions where the upper and lower jaws are underdeveloped and may result in an obstructed upper airway.

 

Some of the warning signs may, but do not necessarily include:

The clinical goal of treating midfacial hypoplasia and/or mandibular retrognathia/retrusion is correcting the maxillo-mandibular skeletal and oral soft tissue structures to eliminate and/or reduce the obstruction of the upper airway.

 

Some of the treatment outcomes may include:

Three-Dimensional Model of The Airway

(Pretreatment)

Three-Dimensional Model of The Airway

(Post Treatment)

The Vivos Therapeutic approach is a safe, non-invasive approach to treating midfacial hypoplasia and/or mandibular retrognathia/retrusion in both children and adults.

In 98% of patients with OSAS, the condition is due to abnormal anatomical features of the soft tissues and/or the structures of the maxillomandibular skeleton that cause a disproportionate anatomy of the airway.*

"

"

ARCH OTOLARYNGOL HEAD NECK SURG/VOL 137 (NO. 10), OCT 2011

Midfacial Hypoplasia & Mandibular Retrognathia

Correcting Midfacial Hypoplasia & Mandibular Retrognathia

Vivos Biomimetic

Oral Appliance Therapy

Vivos Therapeutics

Pneumopedics®

Vivos biomimetic oral appliance therapy is specifically designed to treat midfacial hypoplasia and/or mandibular retrognathia/retrusion. Vivos Therapeutics is registered with the Federal Drug Administration as a Specification Developer and to date has several medical devices registered:

Pneumopedics® is physiologic remodeling of the upper airway via treatment-induced changes. The Vivos System incorporates the Pneumopedics® protocol using biomimetic oral appliance therapy for addressing midfacial hypoplasia and/or mandibular retrognathia/retrusion.

Articles &

Publications

DOWNLOAD

Journal of Sleep Disorders & Therapy

 

A Novel Combined Protocol for the Resolution of Severe Obstructive Sleep Apnea

Abstract

A 27-year-old woman was referred to our office for a dental assessment regarding temporomandibular joint pain. On initial screening, she was found to be at high risk for obstructive sleep apnea, and subsequently underwent polysomnography, which revealed an apnea-hypopnea index of 118 hr-1. Her condition was initially controlled with continuous positive airway pressure therapy, which she did not tolerate well.

 

Therefore, treatment proceeded with biomimetic oral appliance therapy. After 10 months of combined continuous positive airway pressure therapy and biomimetic oral appliance therapy, the apnea-hypopnea index fell to 1 hr-1 and obstructive sleep apnea could not be observed with or without the appliances in situ. We conclude that combined continuous positive airway pressure therapy and biomimetic oral appliance therapy might represent a potential cure of severe cases obstructive sleep

apnea in certain patients.

 

Explore scientific articles and publications

EXPLORE

Healthcare

Professionals

About Our

Company

®

© 2019 Vivos Therapeutics, Inc.  ALL RIGHTS RESERVED

All content found on the vivoslife.com website, including text, images, audio, or other formats were created for informational purposes only. The content of this website is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. Individual results may vary. Nothing contained in this website infers or creates a warranty, promise, or guarantee of any kind with respect to the clinical outcome or result from treatment using the Vivos technology. The use of the Vivos technologies by any patient must always occur under the direction and supervision of a qualified, trained, and licensed dentist, physician or other qualified health provider, working in close collaboration with qualified medical personnel.